Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CICC Has Second Close of Biomedical Fund at $648 Million

publication date: Jan 14, 2021

CICC Capital announced its RMB biomedical private equity fund, called CICC Qide, has raised $648 million as of the second closing. In February of 2020, CICC announced the first close with $247 million. The fund has already invested in over 20 companies, with several portfolio companies now starting the IPO process. CICC Capital, a platform for Beijing's China International Capital Corporation, manages RMB and USD funds that are aimed at venture capital, growth, buyout, fund of funds and distressed opportunities. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital